



**ISPOR 7th Asia-Pacific
Conference**

3-6 September, 2016
Suntec Singapore Convention &
Exhibition Center
Singapore



Pharmacoeconomics and Outcomes Research in Asia-Pacific: Challenges, Opportunities, and Future Direction

Monday Research Poster Presentations

Poster Display Hours – 8:30 AM - 7:30 PM
Poster Author Discussion Hour – 6:30 PM - 7:30 PM

POSTER PRESENTATIONS:

PRM:	RESEARCH ON METHODS	ROWS A-E
PMD:	MEDICAL DEVICES/DIAGNOSTICS	ROWS E-H
PCV:	CARDIOVASCULAR DISORDERS	ROWS H-N
PND:	NEUROLOGICAL DISORDERS	ROWS N-P
PRS:	RESPIRATORY-RELATED DISORDERS	ROWS P-R
PSY:	SYSTEMIC DISORDERS/CONDITIONS	ROWS R-T

Research Poster Presentations

Acceptance Code	PDF Page #	Topic – Subtopic
PRM1-PRM10	105	Research on Methods - Clinical Outcomes Methods
PRM11-PRM15	109	Research on Methods - Cost Methods
PRM16-PRM21	112	Research on Methods - Databases & Management Methods
PRM22-PRM29	114	Research on Methods - Modeling Methods
PRM30-PRM38	118	Research on Methods - Patient-Reported Outcomes Studies
PRM39-PRM42	121	Research on Methods - Statistical Methods
PRM43	123	Research on Methods - Study Design
PRM44-PRM48	123	Research on Methods - Conceptual Papers
PMD1-PMD8	125	Medical Devices/Diagnostics - Clinical Outcomes Studies
PMD9-PMD18	129	Medical Devices/Diagnostics - Cost Studies
PMD19	133	Medical Devices/Diagnostics - Patient-Reported Outcomes & Patient Preference Studies
PMD-20-PMD31	133	Medical Devices/Diagnostics - Health Care Use & Policy Studies
PCV1-PCV14	139	Cardiovascular Disorders - Clinical Outcomes Studies
PCV15-PCV32	144	Cardiovascular Disorders - Cost Studies
PCV33-PCV46	152	Cardiovascular Disorders - Patient-Reported Outcomes & Patient Preference Studies
PCV47-PCV61	158	Cardiovascular Disorders - Health Care Use & Policy Studies
PND1-PND7	165	Neurological Disorders - Clinical Outcomes Studies
PND8-PND11	168	Neurological Disorders - Cost Studies
PND12-PND13	170	Neurological Disorders - Patient-Reported Outcomes & Patient Preference Studies
PND14-PND16	171	Neurological Disorders - Health Care Use & Policy Studies
PRS1-PRS4	172	Respiratory-Related Disorders - Clinical Outcomes Studies
PRS5-PRS10	174	Respiratory-Related Disorders - Cost Studies
PRS11-PRS12	177	Respiratory-Related Disorders - Patient-Reported Outcomes & Patient Preference Studies
PRS13-PRS21	178	Respiratory-Related Disorders - Health Care Use & Policy Studies
PSY1-PSY7	182	Systemic Disorders/Conditions - Clinical Outcomes Studies
PSY8-PSY14	185	Systemic Disorders/Conditions - Cost Studies
PSY15-PSY17	188	Systemic Disorders/Conditions - Patient-Reported Outcomes & Patient Preference Studies
PSY18-PSY27	189	Systemic Disorders/Conditions - Health Care Use & Policy Studies

RESEARCH POSTER PRESENTATIONS - SESSION II

RESEARCH ON METHODS STUDIES

RESEARCH ON METHODS - Clinical Outcomes Methods

- PRM1 A1 HEPATITIS B VACCINATION IN DIALYSIS PATIENTS. IS IT REALLY PROTECTIVE?**
Kaza S¹, Prasad S², Prasad N S², Prabhu RA², Rangaswamy D¹,¹Kasturba Medical College Manipal, Manipal University, Manipal, Udupi, Karnataka, India, ²Manipal University, Manipal, India
- PRM2 A2 EVALUATION OF QUALITY OF PHARMACOECONOMIC STUDIES IN ASIA PACIFIC AND IDENTIFICATION OF INFLUENCING VARIABLES**
Pandey R, Pandey P, Shrivastav V, Mittra S, Shah V, SIRO Clinpharm Pvt Ltd, Maharashtra, India
- PRM3 A3 ADAPTING DATA SOURCES FOR SYSTEMATIC LITERATURE REVIEW RETRIEVES ADDITIONAL DATA RELEVANT FOR ASIAN HTA**
O'Rourke JM¹, Halfpenny NJ², Quigley JM², Scott DA¹,¹ICON Health Economics & Epidemiology, Abingdon, UK, ²ICON Clinical Research UK Ltd, Abingdon, UK
- PRM4 A4 THE MORPHOLOGICAL STUDY OF HUMAN BROWN ADIPOSE TISSUE DURING FETAL DEVELOPMENT**
Ganlkhagva N, Dagdanbazar N, Sundui E, Jamsranjav O, Mongolian National University Medical Sciences, Ulaanbaatar, Mongolia
- PRM5 A5 TO EVALUATE THE OUTCOMES OF CONCOMITANT CHEMORADIOTHERAPY FOLLOWED BY EXTENDED ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA - A RETROSPECTIVE STUDY**
Gupta S¹, Gupta SK², Mathur R²,¹Delhi Institute of Pharmaceutical Sciences and Research, NEW DELHI, India, ²Delhi Institute of Pharmaceutical Sciences and Research, University of Delhi, India., Delhi, India
- PRM6 A6 COST-EFFECTIVENESS ANALYSIS OF ANTIHYPERTENSIVE DRUGS USAGE BY COMBINATION OF ACEI – CCB AND ACEI – DIURETIC IN OUTPATIENT HYPERTENSION THERAPY AT RSAL MINTOHARDJO JAKARTA (JULY-NOVEMBER 2015)**
Hasan D, Faculty Of Medicine and Health Science, Islamic State University, Jakarta, Indonesia
- PRM7 A7 THE BURDEN ASSOCIATED WITH INTRA-OPERATIVE ANASTOMOTIC LEAKS IN COLORECTAL SURGERY**
Schiff A¹, Roy S², Pignot M³, Laschke K³, Stadler J³, Ghosh SK⁴, Yin C⁵, Fegelman E¹,¹Johnson & Johnson (Ethicon), Cincinnati, OH, USA, ²Johnson and Johnson Global Surgery, Somerville, NJ, USA, ³Kantar Health, Munich, Germany, ⁴Global Health Economics and Market Access, Ethicon, Inc., Cincinnati, OH, USA, ⁵JnJ Medical AP, Singapore, Singapore
- PRM8 A8 EMPIRICAL CALIBRATION OF HEPATITIS C VIRUS (HCV) NATURAL HISTORY MODEL TO THE CHINESE HCV-INFECTED POPULATION**
Lee K, Goldhaber-Fiebert J, Stanford University, Stanford, CA, USA
- PRM9 A9 CAN PHARMACEUTICAL CARE INTERVENTION IMPROVE LIPID PROFILE IN TYPE 2 DIABETES PATIENTS; A PROSPECTIVE INTERVENTION STUDY IN A TERTIARY HOSPITAL IN NIGERIA**
Ogbonna BO, UNIVERSITY OF BENIN, BENIN CITY, EDO STATE, Nigeria
- PRM10 A10 A METHODOLOGICAL ISSUE IN EFFECTIVENESS STUDIES OF MALARIA VACCINES AND CHEMOPREVENTION**
Cheung YB¹, Xu Y¹, Cairns M², Milligan P²,¹Duke-NUS Medical School, Singapore, Singapore, ²London School of Hygiene & Tropical Medicine, London, United Kingdom of Great Britain and Northern Ireland

RESEARCH ON METHODS - Cost Methods

- PRM11 B1 A SYSTEMATIC REVIEW ON METHODOLOGICAL HETEROGENEITY IN ESTIMATING PRODUCTIVITY LOSS ASSOCIATED WITH COLORECTAL CANCER**
Harsono K¹, Soon S¹, Chia JW², Tan WS³, Chew MH³, Wee HL¹,¹National University of Singapore, Singapore, Singapore, ²National Cancer Centre Singapore, Singapore, Singapore, ³Singapore General Hospital, Singapore, Singapore
- PRM12 B2 HOW ARE BUDGET IMPACT CONSIDERATIONS CAPTURED WITHIN ECONOMIC EVALUATIONS? A SYSTEMATIC REVIEW OF THE LITERATURE FOCUSED ON ROTAVIRUS VACCINE**
Carvalho N, University of Melbourne, Carlton, Australia
- PRM13 B3 COST ASSESSMENT FOR HEALTHY DIET IN THE STATE OF PENANG, MALAYSIA**
Saleem F, Hassali MA, Universiti Sains Malaysia, Penang, Malaysia
- PRM14 B4 A REVIEW OF ASSESSMENTS OF THE QUALITY OF PHARMACOECONOMIC EVALUATIONS IN CHINA**
Zhou J¹, Millier A², Cheng X³, Aballea S², Toumi M⁴,¹Creativ-Ceutical, Beijing, China, ²Creativ-Ceutical, Paris, France, ³Creativ-Ceutical, Hong Kong, Hong Kong, ⁴Aix-Marseille University, Marseille, France
- PRM15 B5 SYSTEMATIC LITERATURE REVIEW AND ASSESSMENT OF THE REPORTING QUALITY OF ECONOMIC EVALUATION STUDIES IN NON-SMALL CELL LUNG CANCER IN CHINA**

Zhou J¹, Ma F¹, Cheng X², Millier A³, Aballea S³, Toumi M⁴,¹Creativ-Ceutical, Beijing, China, ²Creativ-Ceutical, Hong Kong, Hong Kong, ³Creativ-Ceutical, Paris, France, ⁴Aix-Marseille University, Marseille, France

RESEARCH ON METHODS - Databases & Management Methods

PRM16 B6 MAPPING OF EXISTING DATA SOURCES FOR THE CONDUCT OF REAL-WORLD STUDIES ON LUNG CANCER IN CHINA
Yuen CY¹, Bergamasco A², Moride Y¹, Faculty of Pharmacy, Université de Montréal, Montreal, QC, Canada, ²YolaRx Consultants, Paris, France

PRM17 B7 ESTABLISHING AN INTERNATIONAL REFERENCE PRICING DATABASE: AN INNOVATIVE TOOL TO SUPPORT DRUG PRICING REFORM IN CHINA
Zhou Y¹, Gao Y¹, Zhang L¹, Xuan D², Zhu S¹, Yang F¹, Xuan J³,¹Shanghai Centennial Scientific Ltd, Shanghai, China, ²Vanderbilt University, Nashville, TN, USA, ³Sun Yat-Sen University, Guangzhou, China

PRM18 B8 MAPPING OF EXISTING DATA SOURCES FOR THE CONDUCT OF REAL-WORLD STUDIES IN PROGRESSIVE SUPRANULCEAR PALSY (PSP) IN NORTH AMERICA, EUROPE AND JAPAN
Bergamasco A¹, Yuen CY², Kou T³, Moride Y², YolaRx Consultants, Paris, France, ²Faculty of Pharmacy, Université de Montréal, Montreal, QC, Canada, ³Bristol-Myers and Squibb, Hopewell, NJ, USA

PRM19 B9 IMPACT AND IMPORTANCE OF REAL WORLD DATA IN ASIA: A PHYSICIAN'S PERSPECTIVE
Courbet T¹, Dreyer NA², Moussalli R³, Wai K⁴, Kaur -⁵,¹Quintiles, Chatswood, Australia, ²Quintiles, Cambridge, MA, USA, ³Quintiles, Inc., Paris, France, ⁴Quintiles, Singapore, Singapore, ⁵, Singapore, Singapore

PRM20 B10 FEASIBILITY OF ELECTRONIC MEDICAL RECORDS IN AUSTRALIA, CHINA, AND JAPAN TO SUPPORT NOVELTY (A NOVEL OBSERVATIONAL LONGITUDINAL STUDY OF PATIENTS WITH ASTHMA AND/OR COPD)
Wang X¹, Gerhardsson de Verdier M², Sveréus A², Hiller J³, Wong D³, Nasuti P³, Jenner H³, McKenney A³,¹AstraZeneca, Gaithersburg, MD, USA, ²AstraZeneca, Gothenburg, Sweden, ³IMS Health, London, UK

RESEARCH ON METHODS - Modeling Methods

PRM22 C1 VALIDATION OF MODEL-SIMULATED CLINICAL OUTCOMES OF ANTIPLATELET THERAPIES IN PATIENTS WITH ACUTE CORONARY SYNDROME
Jiang M, You J, The Chinese University of Hong Kong, Shatin, Hong Kong

PRM23 C2 BEWARE THE IMPACT OF DISCOUNT RATES IN THE ASSESSMENT OF HPV VACCINES
Lloyd E¹, Jang H², Sohn W¹, Van Krieking GM³,¹GlaxoSmithKline, Singapore, Singapore, ²GlaxoSmithKline, Seoul, South Korea, ³GlaxoSmithKline, Wavre, Belgium

PRM24 C3 THE VALIDITY OF MARKOV MODEL FOR THE PROGNOSTIC ESTIMATION OF CHRONIC KIDNEY DISEASE
Hiragi S¹, Tamura H¹, Goto R², Kuroda T¹,¹Kyoto University Hospital, Kyoto, Japan, ²Keio Business School, Yokohama, Japan

PRM25 C4 VARIATION OF DATA SOURCE USED FOR BASELINE POPULATION AND FOR NATURAL COURSE OF ALZHEIMER'S DISEASE PROGRESSION IN MODEL-BASED ECONOMIC EVALUATION OF TREATMENT OF AD
Lerjanyakun V, Kunisawa S, Imanaka Y, Kyoto University, Kyoto, Japan

PRM26 C5 PRECISION HEOR: USING BIG DATA TO DEVELOP A PERSONALIZED MODELING FRAMEWORK
Chen Y¹, Wang BC², Furnback W³, Garrison LP², Dong P¹, Xie G⁴, Guzauskas GF², Gu C¹,¹Pfizer Investment Co., Ltd., Beijing, China, ²University of Washington, Seattle, WA, USA, ³Elysia Group, LLC, New York, NY, USA, ⁴IBM Research, Beijing, China

PRM27 C6 DIFFERENCES IN COST-EFFECTIVENESS ESTIMATES FOR CHRONIC HEPATITIS C TREATMENT AMONG COHORT MARKOV MODEL, MARKOV MICROSIMULATION AND DISCRETE EVENT SIMULATION
Zhou H¹, Zhao YJ¹, Wojciech AC², Lin L¹, Caro JJ³, Moller J⁴, Dan YY⁵, Lim BP¹,¹Pharmacy and Therapeutics Office, Group Corporate Development, National Healthcare Group, Singapore, Singapore, ²TreeAge Software, Inc. USA, Williamstown, MA, USA, ³Evidera, Lexington, MA, USA, ⁴Faculty of Medicine, Lund University, Lund, Sweden, ⁵Department of Medicine, Yong Loo Lin School of Medicine, National University Hospital, Singapore, Singapore

PRM28 C7 A COMPREHENSIVE ECONOMIC MODEL FOR DEMENTIA: DIAGNOSIS, DISEASE PROGRESSION AND SERVICE DELIVERY

Thokala P¹, Brennan A¹, Lafortune L², Brayne C²,¹University of Sheffield, Sheffield, UK, ²University of Cambridge, Cambridge, UK

PRM29 C8 ON A DESIGN ISSUE OF EQ-5D-3L VALUATION STUDIES: SHOULD LIKELIHOOD OF THE HEALTH STATES BE CONSIDERED?

Yang Z¹, Luo N², van Busschbach J³, Stolk E⁴,¹Erasmus University Rotterdam, Rotterdam, The Netherlands, ²National University Singapore, Singapore, Singapore, ³Erasmus MC, Rotterdam, The Netherlands, ⁴EuroQol Research Foundation, Rotterdam, The Netherlands

RESEARCH ON METHODS - Patient-Reported Outcomes Studies

PRM30 C9 RELIABILITY AND VALIDITY OF THE SHORT-FORM 36 (SF-36) HEALTH SURVEY IN PATIENTS WITH SPONDYLOARTHRITIS
Kwan YH¹, Yong ST², Fong W², Lui NL², Malhotra R¹, Ostbye T¹, Thumboo J³,¹Duke-NUS Medical School, Singapore, Singapore, ²Singapore General Hospital, Singapore, Singapore, ³Singhealth, Singapore, Singapore

PRM31 C10 A COMPARISON OF EUROQOL EQ-5D AND SF-36 FOR ESTIMATING HEALTH-ADJUSTED LIFE-EXPECTANCY (HALE) IN

TAIWAN

Liao C, Tan EC, Yang M, National Taiwan University, Taipei, Taiwan

- PRM32 D1 **PSYCHOMETRIC PROPERTIES AND MEASUREMENT EQUIVALENCE OF THE ENGLISH AND CHINESE VERSIONS OF THE BECK ANXIETY INVENTORY IN PATIENTS WITH BREAST CANCER**
Ng T¹, Yeo HL¹, Shwe M¹, Gan YX², Chan A¹,¹National University of Singapore, Singapore, Singapore, ²National Cancer Center Singapore, Singapore, Singapore
- PRM33 D2 **VALIDITY OF CHILD HEALTH-6 DIMENSION(CH-6D) FOR ADOLESCENTS**
Kang E, Soonchunhyang University, Asan city, South Korea
- PRM34 D3 **REAL TIME PATIENT REPORTED OUTCOMES ASSESSMENT IN ROUTINE RHEUMATOLOGY CLINIC - FEASIBILITY STUDY OF MYRA TOUCH**
Lee YY¹, Gandhi C², D'Souza B², Ramanujam S², Hong HC², Nadiah NM², Gun SC²,¹Pfizer Malaysia, Kuala Lumpur, Malaysia, ²Hospital Tuanku Ja'afar, Seremban, Malaysia
- PRM35 D4 **A COMPARISON OF EQ-5D-3L INDEX SCORES USING FOREIGN VALUE SETS FOR INDONESIAN SAMPLE WITH CERVICAL CANCER**
Endarti D¹, Riewpaiboon A², Thavorncharoensap M², Praditsithikorn N³, Hutubessy R⁴, Kristina SA¹,¹Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, Indonesia, ²Faculty of Pharmacy, Mahidol University, Bangkok, Thailand, ³Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Bangkok, Thailand, ⁴World Health Organization, Geneva, Switzerland
- PRM37 D5 **THE STUDY OF THE INCIDENCE, ETIOLOGY AND RISK FACTORS FOR CONSTIPATION WITHIN CANCER PALLIATIVE CARE PATIENTS**
Munkhtuya E¹, Odontuya D², Enkhbolor G², Sarantsetseg M², Dolgorsuren B²,¹Mongolian National University of Medical Sciences, School of Nursing, Ulaanbaatar, Mongolia, ²Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia
- PRM38 D6 **PATIENTS' EDUCATIONAL BACKGROUND WAS ASSOCIATED WITH THE VALIDITY AND RELIABILITY OF A HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE**
Cheung YB¹, Lee CF², Luo N³, Ng R⁴,¹Duke-NUS Medical School, Singapore, Singapore, ²Singapore Clinical Research Institute, Singapore, Singapore, ³Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore, ⁴National Cancer Center, Singapore, Singapore

RESEARCH ON METHODS - Statistical Methods

- PRM39 D7 **ESTIMATING THE IMPACT OF DIRECT-TO-CONSUMER ADVERTISING OF PHARMACY ONLY MEDICINE USING DISCRETE CHOICE EXPERIMENTS**
Goodall S, Zhao F, Street D, Viney R, University of Technology Sydney, Sydney, Australia
- PRM40 D8 **A PROPOSED MODEL FOR THE STUDY OF THE LONGITUDINAL BEHAVIOR OF PREVALENCE RATES**
Song X¹, Juneau P², Meyer N³,¹Truven Health Analytics, Shrewsbury, MA, USA, ²Truven Health Analytics, an IBM Company, Boyds, MD, USA, ³Truven Health Analytics, Cambridge, MA, USA
- PRM41 D9 **DATA IMPUTATION FOR MISSING VALUES IN A CLAIM-BASED ADMINISTRATIVE DATABASE: COMPARISON OF IMPUTATION APPROACHES**
Tai M¹, Onukwugha E², dosReis S²,¹Pharmerit International, Bethesda, MD, USA, ²University of Maryland School of Pharmacy, Baltimore, MD, USA
- PRM42 D10 **ANALYSIS ON THE UTILIZATION STATUS OF ESSENTIAL MEDICINES IN BEIJING'S COMMUNITY HEALTH INSTITUTIONS**
Zhang F¹, Li SC²,¹Shenyang Pharmaceutical University, shenyang, China, ²University of Newcastle, Callaghan, NSW, Australia

RESEARCH ON METHODS - Study Design

- PRM43 E1 **WAS THE CONSISTENCY OF DATA IMPROVED AFTER SEPARATING THE BETTER THAN HEALTH (BTD) AND WORSE THAN DEATH (WTD) TASKS AND IMPLEMENTING A FEEDBACK MODULE (FB) IN COMPOSITE TIME TRADE OFF (CTTO) EXERCISE?**
Wong EL¹, Stolk E², Cheung AW¹, Wong AY¹, Visser M³, Shah K⁴,¹The Chinese University of Hong Kong, Shatin, Hong Kong, ²Erasmus MC, Rotterdam, The Netherlands, ³Medical Psychology and Psychotherapy, The Netherlands, The Netherlands, ⁴Office of Health Economics, London, UK

RESEARCH ON METHODS - Conceptual Papers

- PRM44 E2 **DICE SIMULATION: A NEW METHOD THAT FACILITATES DECISION-ANALYTIC MODELING**
Caro JJ¹, Moller J²,¹Evidera, Lexington, MA, USA, ²Faculty of Medicine, Lund University, Lund, Sweden
- PRM45 E3 **A SYNOPSIS ON OPPORTUNITIES AND CHALLENGES OF PATIENT RELATED OUTCOME MEASURES (PROMS) FOR PATIENT BENEFITS**
Desai A, Mahajan N, Pillai R, Johnson & Johnson Medical India, Behind Majas Bus Depot, Jogeshwari (East), Mumbai - 400060, India
- PRM46 E4 **A CALCULATING ANALYSIS MODEL ON DISABILITY ADJUSTED OF LIFE YEARS AMONG PATIENTS SUFFERING FROM**

ALZHEIMER'S: BASED ON THE IMPROVEMENT OF MULTI-STATE MARKOV MODEL

Wu J, Liu J, Zhu B, Mao Y, Xi'an Jiaotong University, Xi'an, China

PRM47 E5 ANTIVIRAL ACTIVITY AND EMBRYONIC TOXICITY OF MOXIDECTIN AGAINST INFLUENZA VIRUS H9

Hameed R¹, **Tahir M**², Azeem S¹, Anjum MS³, Iqbal MZ⁴,¹University of Veterinary & Animal Sciences Lahore, Pakistan, Lahore, Pakistan, ²University of Veterinary & Animal Sciences Lahore, Pakistan, Lahore, Malaysia, ³PMAS- Arid Agriculture University, Rawalpindi, Pakistan, Rawalpindi, Pakistan, ⁴AIMST University,, Bedong, Kedah Darul Aman, Malaysia, Malaysia

PRM48 E6 EBOLA VIRUS DISEASE AND ITS MANAGEMENT- A REVIEW

Palanisamy S, Marikannan M, International Medical University, Kuala Lumpur, Malaysia

SELECTED HEALTH CARE TREATMENT STUDIES

MEDICAL DEVICES/DIAGNOSTICS - Clinical Outcomes Studies

PMD1 E7 STUDY OF CONTRAST INDUCED NEPHROPATHY IN PATIENTS UNDERGOING CARDIAC CATHETERIZATION: UPPER EGYPT EXPERIENCE

Kassem AM, Shazly SE, Sohag Faculty of Medicine, Sohag, Egypt

PMD2 E8 SITUATION AND IMPACT OF INSULIN PEN NEEDLE REUSE FOR PATIENTS WITH DIABETES IN CHINA

Liu T¹, Cui B², Zhong J², Yu K¹, Zhao Z¹, Tao L³, Ren X⁴,¹Beijing Tiantan Hospital, Beijing, China, ²Peking University, Beijing, China, ³Beijing Medical Economics Research Association, Beijing, China, ⁴Becton Dickinson Medical Devices (Shanghai) Co Ltd., Shanghai, China

PMD3 E9 DIAGNOSTIC ACCURACY OF ASSESSMENT METHODS FOR DIAGNOSING DIABETIC PERIPHERAL NEUROPATHY (DPN): A SYSTEMATIC REVIEW AND META-ANALYSIS: AN EVIDENCE BASED APPROACH

Gangavarapu VM, NIPER Mohali, Mohali, India

PMD4 E10 CLINICAL AND ECONOMIC IMPACT OF BLOOD CULTURES AMONG ADULT PATIENTS ADMITTED WITH PNEUMONIA IN TIANJIN, CHINA

Yu N¹, Wu J¹, Li P²,¹Tianjin University, Tianjin, China, ²Becton, Dickinson and Company, Shanghai, China

PMD5 F1 AN OBSERVATIONAL STUDY ON RISK FACTORS AND CLINICAL PRESENTATION S IN STROKE PATIENTS

Gopu D, St. Peter's Institute of Pharmaceutical Sciences, Kazipet, India

PMD6 F2 A HEALTH TECHNOLOGY ASSESSMENT OF SINGLE BALLOON VALVULOPLASTY

Sharma M, Chahar A, Sharma J, WHO Collaborating Centre for Priority Medical Devices & Health Technology Policy, NHSRC, New Delhi, India

PMD7 F3 SUBATMOSPHERIC PRESSURE THERAPY EFFICIENCY FOR THE TREATMENT OF PRESSURE ULCERS: A HEALTH TECHNOLOGY ASSESSMENT

Meireles IB¹, **Tolentino AC**², Lyra da Silva RC³,¹Hospital Federal Cardoso Fontes, Rio de Janeiro, Brazil, ²HUPE/UERJ Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ³Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, Brazil

PMD8 F4 A CLINICAL LITERATURE REVIEW OF CORONARY ARTERY CALCIFICATION AND CURRENT TREATMENT OUTCOMES IN JAPAN

Martinsen BJ¹, Zhao R², Igyarto Z²,¹Cardiovascular Systems, Inc., St. Paul, MN, USA, ²Cardiovascular Systems, Inc., St Paul, MN, USA

MEDICAL DEVICES/DIAGNOSTICS - Cost Studies

PMD9 F5 ECONOMIC STUDY OF NON-PHARMACOLOGICAL AND PHARMACOLOGICAL TREATMENT FOR OSTEOPOROSIS VERTEBRAL FRACTURE AND BONE EVENTS IN ONCOLOGY PATIENTS IN A HEALTH INSURANCE PROVIDER IN A LATIN AMERICA COUNTRY

Tanaka E¹, Itria A², Tanaka F¹, Barbosa M³, Massuda EM⁴, Favoreto C⁴, Huang W⁵, Kuabara R⁶, Saldanha C⁷, Tolentino AC⁸,¹CURITIBA'S HEALTH INSTITUTE, CURITIBA, PARANÁ, Brazil, ²GOIAS UNIVERSITY, GOIANIA, GO, Brazil, ³SPINOMED LAB RESEARCH, BERLIN, Germany, ⁴UniCesumar, MARINGÁ PR, Brazil, ⁵CASSI, BRASILIA DF, Brazil, ⁶GOIANIA STATE HEALTH CARE, GOIANIA, GO, Brazil, ⁷SANTA CASA HOSPITAL, PORTO ALEGRE, RS, Brazil, ⁸UERJ HEALTH ECONOMICS & OUTCOMES RESEARCH, Rio de Janeiro, Brazil

PMD10 F6 SCREENING RATE FOR DIABETIC RETINOPATHY AND MACULAR EDEMA IN PATIENTS WITH DIABETES AND THEIR TREATMENT COSTS IN THE UNITED ARAB EMIRATES

Je S, Lee S, Seong J, Lee S, Suh D, Chung-Ang University, Seoul, South Korea

PMD11 F7 TELEDERMOSCOPY AS A REFERRAL METHOD IN AUSTRALIA: A DECISION ANALYTIC MODEL

Snoswell C¹, Gordon LG², Janda M³, Finnane A¹, Whitty JA¹,¹The University of Queensland, Brisbane, Australia, ²Griffith University, Logan, Australia, ³Queensland University of Technology, Kelvin Grove, Australia

PMD13 F9 COST-EFFECTIVENESS ANALYSIS OF XPRT MTB/RIF ASSAY FOR DIAGNOSING TUBERCULOSIS IN MALAYSIA USING DYNAMIC TRANSMISSION MODEL

Lee KK¹, **Fun WH**², Wu DB¹, Cheong YM¹, Mohamad Noordin N³,¹Monash University Malaysia, Subang Jaya, Malaysia, ²Institute For Health Systems Research, Setia Alam, Malaysia, ³National Public Health Laboratory, Sungai Buloh, Malaysia

- PMD14 F10 COST-EFFECTIVENESS OF INTERFERON-GAMMA RELEASE ASSAY FOR TUBERCULOSIS SCREENING OF MENTAL PATIENTS WITH TOBACCO SMOKING**
Kowada A, Ota City Office, Tokyo, Japan
- PMD15 G1 HEALTH ECONOMIC EVALUATION OF WATCHMANTM LEFT ATRIAL APPENDAGE CLOSURE (LAAC) DEVICE VESUS LONG-TERM WARFARIN THERAPY IN PATIENTS WITH ATRIAL FIBRILLATION (AF) IN CHINA**
Zhu S¹, Zhang M², Zeng Z², Shi J², Chen G², Xuan J³,¹Shanghai Centennial Scientific Co.,Ltd, Shanghai, China, ²Boston Scientific, Shanghai, China, ³Sun Yat-Sen University, Guangzhou, China
- PMD16 G2 COST-EFFECTIVENESS OF IMPLEMENTING COMPUTED TOMOGRAPHY SCREENING FOR EARLY DIAGNOSIS OF LUNG CANCER IN TAIWAN**
Wang J, National Cheng Kung University College of Medicine, Tainan, Taiwan
- PMD17 G3 COST-EFFECTIVENESS ANALYSIS OF NATIONAL SCREENING PROGRAM FOR PULMONARY TUBERCULOSIS IN KOREA**
Yang J¹, Shin M¹, Tchoe H¹, Kwon H², Ahn J³, Shin S¹,¹National Evidence based Health-care Collaborating Agency, Seoul, South Korea, ²Koshin University Gospel Hospital, Busan, South Korea, ³Department of Health Convergence, Ewha Womans University, Seoul, South Korea
- PMD18 G4 COST EFFECTIVENESS OF CONTRAST-ENHANCED LIVER MRI IN THE CHARACTERISATION OF SUSPECTED LIVER LESIONS IN PATIENTS WITH COLORECTAL CANCER**
Saing S¹, Haywood P¹, Goodall S²,¹University of Technology Sydney, Haymarket, Australia, ²University of Technology Sydney, Sydney, Australia

MEDICAL DEVICES/DIAGNOSTICS - Patient-Reported Outcomes & Patient Preference Studies

- PMD19 G5 HEALTH UTILITY MEASURED WITH EQ-5D-5L IN JAPANESE PATIENTS UNDERGOING HEMODIALYSIS**
Saito S¹, Noto S², Miyazaki M³,¹Okayama University, Okayama, Japan, ²Niigata University of Health and Welfare, Niigata, Japan, ³Saiwaicho-kinen Hospital, Okayama, Japan

MEDICAL DEVICES/DIAGNOSTICS - Health Care Use & Policy Studies

- PMD20 G6 STATUS AND EXPENSES: RE-USE OF INSULIN SYRINGE NEEDLES IN THE DIABETIC PATIENTS IN BEIJING**
Cui B¹, Tao L², Zhong J¹, Zhao Z³,¹Peking University, Beijing, China, ²Beijing Medical Economics Research Association, Beijing, China, ³Beijing Tiantan Hospital, Beijing, China
- PMD21 G7 CHALLENGES IN THE ASSESSMENT OF MEDICAL DEVICES: RECOMMENDATIONS FROM THE MEDTECHTA PROJECT**
Drummond M¹, Tarricone R², Torbica A²,¹University of York, Heslington, York, UK, ²Bocconi University, Milan, Italy
- PMD22 G8 CLOSED-SYSTEM TRANSFER DEVICE FOR PREPARATION OF ANTINEOPLASTIC DRUGS IN A MALAYSIAN PUBLIC HOSPITAL: IS IT TRULY COST SAVING?**
Chan H¹, **Lim CJ**², Hassali MA², Saleem F²,¹Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia., Alor Setar., Malaysia, ²Universiti Sains Malaysia, Penang, Malaysia
- PMD23 G9 HEALTH ECONOMIC EVALUATION OF HYDROPHILIC COATED VERSUS NON-COATED URINARY CATHETERS FOR INTERMITTENT USE IN JAPAN**
Neovius K¹, Åberg-Håkansson M², Lundqvist T²,¹Cyclo AB, Stockholm, Sweden, ²Wellspect HealthCare, Mölndal, Sweden
- PMD24 G10 HEALTH ECONOMICS ANALYSES FOR MEDICAL DEVICES IN ASIA: A LITERATURE REVIEW**
Nakahara N¹, Dunlop S²,¹Zimmer Biomet G.K., Tokyo, Japan, ²Zimmer Biomet, Belrose, Australia
- PMD25 H1 THE EFFECTIVENESS OF PRE-FILLED VERSUS MANUALLY FILLED FLUSH SYRINGES IN INTRAVASCULAR DEVICES MAINTENANCE: A META-ANALYSIS**
Tian L, Zhou T, Ma A, Liu Q, Zhang S,¹China Pharmaceutical University, Nanjing, China
- PMD26 H2 ADVERSE DRUG REACTIONS OF RADIOGRAPHIC CONTRAST MEDIA USED IN COMPUTED TOMOGRAPHY AND MAGNETIC RESONANCE IMAGING IN INDIA**
Rajesh R¹, Anjali T¹, Chandrakant S²,¹Manipal college of pharmaceutical sciences, Manipal University, MANIPAL, INDIA, India, ²Dept of Radiology, Kasturba Medical College, Manipal University, MANIPAL, INDIA, India
- PMD27 H3 ECONOMIC ANALYSES OF DIAGNOSTIC TESTS FOR HCC SURVEILLANCE: A SYSTEMATIC REVIEW**
Tchoe H¹, Suh J², Yang J¹, Yu E², Shin S¹,¹National Evidence based Health-care Collaborating Agency, Seoul, South Korea, ²National Evidence based Healthcare Collaborating Agency, Seoul, South Korea
- PMD28 H4 RAPID HEALTH TECHNOLOGY ASSESSMENT – VALVELESS TROCAR SYSTEM FOR ADVANCED LAPAROSCOPIC / ROBOTIC SURGERY**
Pwee KH, Eastern Health Alliance, Singapore, Singapore
- PMD29 H5 UNDERSTANDING THE IMPACT OF LABORATORY PERFORMANCE ON OUTCOMES IN A SCREENING POPULATION FOR CARDIOVASCULAR DISEASE IN TAIWAN**
Wu LC¹, **Juelicher P**², Liu LC³,¹ChiMei Medical Center, Tainan, Taiwan, ²Abbott, Wiesbaden, Germany, ³ChiMei Medical Center, Health Management Center, Tainan, Taiwan

PMD30 H6 PRIORITY SETTING OF MEDICAL DEVICE FOR PATIENT SAFETY IN KOREAN HOSPITALS

Kim S, Ko E, NECA, Seoul, South Korea

PMD31 H7 DO WE REALLY KNOW WHEN WE SHOULD SCREEN FOR HEPATITIS B & C BEFORE STARTING IMMUNOSUPPRESSIVE THERAPY ?

Annem C¹, Arora S¹, Block J¹, **Jolly M**²,¹RUSH UNIVERSITY, CHICAGO, IL, USA, ²Rush University Medical Center, Chicago, IL, USA

DISEASE- SPECIFIC STUDIES

CARDIOVASCULAR DISORDERS - Clinical Outcomes Studies

PCV1 H8 SYSTEMIC ADVERSE DRUG REACTIONS OF ANTIHYPERTENSIVE AGENTS

Subedi N, College of Medical Sciences, Chitwan, Nepal

PCV2 H9 RISK OF CARDIOVASCULAR DISEASE IN TYPE 2 DIABETIC WOMEN ON SULFONYLUREAS: A RETROSPECTIVE CASE-CONTROL STUDY

Johnson N¹, DAS P², Goud Y², Preshanth J², Shetty R²,¹manipal college of pharmaceutical sciences, manipal, India, ²Manipal University, manipal, India

PCV3 H10 IMPACT OF POTENTIAL DRUG INTERACTIONS IN CARDIAC PATIENTS ON MORBIDITY RISK: AN OBSERVATIONAL PROSPECTIVE APPROACH

Fatima A¹, Pal M¹, Bandari S²,¹St.Peter's Institute of Pharmaceutical Sciences, Warangal, Telangana, India, ²St Peter's Institute of Pharmaceutical sciences, Hanamkonda, India

PCV4 I1 THE IMPACT OF DEMENTIA ON THE OUTCOMES OF TREATMENTS FOR ACUTE CORONARY SYNDROME

Choo DW, Wang J, Chien K, Wu FL, Lin Z, National Taiwan University, Taipei, Taiwan

PCV5 I2 ACCELERATED/MALIGNANT HYPERTENSION WITH A DIAGNOSTIC AMBIGUITY: A RETROSPECTIVE COHORT STUDY

Srujitha M, manipal university, manipal, India

PCV6 I3 ASSESSMENT OF SECONDARY RECURRENCE OF STROKE IN ASPIRIN-CLOPIDOGREL COMBINATION THERAPY AND ASPIRIN MONOTHERAPY IN TRANSIENT ISCHEMIC ATTACK PATIENTS IN SOUTH INDIA: A COMPARATIVE STUDY

Pal M¹, Prasad O², Fatima A¹, Bakki C³, Ahmed M⁴,¹St.Peter's Institute of Pharmaceutical Sciences, Warangal, Telangana, India, ²Rohini Super speciality Hospitals, Warangal, India, ³St Peter's Institute of Pharmaceutical sciences, Warangal, India, ⁴St.Peter's Institute of Pharmaceutical Sciences, Warangal, India

PCV7 I4 A PROSPECTIVE STUDY OF ANTIHYPERTENSIVE DRUGS UTILIZATION PATTERN IN OUTPATIENTS OF A TERTIARY CARE TEACHING HOSPITAL

Chakka G¹, Thattakudian Sheikuduman MS¹, B N¹, K PL¹, K P¹, R VA¹, M SR²,¹Annamacharya College of Pharmacy, YSR Kadapa, India, ²Rajiv Gandhi Institute of Medical Sciences, AP, India

PCV8 I5 CORRELATION BETWEEN TEA CONSUMPTION AND PREVALENCE OF HYPERTENSION AMONG SINGAPOREAN CHINESE RESIDENTS OVER 40

Li W¹, Yang J², Li SC³, Ho CL⁴,¹Rutgers University, Piscataway, NJ, USA, ²National University Hospital System, Singapore, Singapore, ³University of Newcastle, Callaghan, NSW, Australia, ⁴National University of Singapore, Singapore, Singapore

PCV9 I6 IMPROVEMENT OF LONG TERM RISKS OF CARDIOVASCULAR EVENTS ASSOCIATED WITH COMMUNITY BASED DISEASE MANAGEMENT IN CHINESE PATIENTS OF THE XIN JIANG AUTONOMOUS REGION OF CHINA

Yang L¹, Cai M¹, Ma M², Huang X², Liu L³, Wang B⁴, Zhu M⁵, Zhu W², Zhe W³, Guan Y³, Kongnakorn T⁶, Peng S⁷, **Hach T**⁸,¹Peking University, Beijing, China, ²Health and Family Planning Commission of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang Uygur Autonomous Region, China, ³Xinjiang Uygur Autonomous Region Center for Disease Control and Prevention, Urumqi, Xinjiang Uygur Autonomous Region, China, ⁴Novartis Pharmaceuticals (China), Shanghai, China, ⁵Novartis Group China, Beijing, China, ⁶Evidera, Bangkok, Thailand, ⁷Evidera, Bethesda, MD, USA, ⁸Novartis International AG, Basel, Switzerland

PCV10 I7 RISK ELEMENTS AND DRUG UTILIZATION IN STROKE PATIENTS

Spurthi T, Bathula G, CES college of pharmacy, kurnool, India

PCV11 I8 HISTORICAL TRENDS AND CORRELATIONS OF PULMONARY EMBOLISM IN TAIWAN

Zhang N, Decision Resources Group, Burlington, MA, USA

PCV13 I10 DIFFERENTIAL FACTORS PREDICTING MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ATHEROSCLEROTIC PATIENTS WITH AND WITHOUT DIABETES MELLITUS

Lin F¹, Tseng W², Wu Y³, Yin W⁴, Li Y⁵, Yeh H⁶, Chen J⁷, Wu C⁸,¹National Taiwan University, Taipei, Taiwan, ²E-Da Hospital, Kaohsiung City, Taiwan, ³Far Eastern Memorial Hospital, New Taipei City, Taiwan, ⁴Cheng-Hsin General Hospital, Taipei, Taiwan, ⁵National Cheng Kung University Hospital, Tainan, Taiwan, ⁶Mackay Medical College, New Taipei City, Taiwan, ⁷Taipei Veterans General Hospital, Taipei City, Taiwan, ⁸National Taiwan University, Taipei City, Taiwan

PCV14 J1 CLINICAL AND ECONOMIC OUTCOMES OF VENOUS THROMBOEMBOLISM (VTE) AMONG HOSPITALIZED PATIENTS IN CHINA: AN ANALYSIS OF ELECTRONIC MEDICAL RECORD DATA

Wu C¹, Chen H², Xie J³, Han S⁴, Horblyuk R⁵, **Wang PF**⁶, Liu L⁷, Lu J⁸, Song H⁴, Du EX⁹, Wu EQ⁹,¹Peking University Shenzhen Hospital, Shenzhen, China, ²Peking University People's Hospital, Beijing, China, ³Analysis Group, Inc., New York, NY,

CARDIOVASCULAR DISORDERS - Cost Studies

- PCV15 J2 PHARMACOECONOMICS ANALYSIS OF ACEI AND ARB AGAINST ESSENTIAL HYPERTENSION: A CASE STUDY OF SHANGHAI**
He J, Hu S, Shanghai Medical Information Center (Shanghai Health Development Research Center), Shanghai, China
- PCV16 J3 PCSK9 INHIBITORS MAY IMPROVE CARDIOVASCULAR OUTCOMES- CAN WE AFFORD THEM?**
Arbel R¹, Hammerman A², Triki N³, Greenberg D⁴, ¹Sapir College, Sderot, Israel, ²Clalit Health Services, Tel-Aviv, Israel, ³Maccabi Healthcare Services, Tel-Aviv, Israel, ⁴Ben-Gurion University of the Negev, Beer Sheva, Israel
- PCV17 J4 TREATMENT OF HYPERTENSION IN ELDERLY - PHARMACOECONOMIC EVALUATION**
Seitaliyeva A, Satbayeva E, Myrzabek B, Pichkhadze G, Ananyeva L, Serdalieva D, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
- PCV18 J5 THE IMPACT OF ATRIAL FIBRILLATION ON THE ECONOMIC BURDEN OF ISCHEMIC STROKE PATIENTS IN BEIJING**
Wen L¹, Wu J², Feng L¹, **Yang L**¹, ¹Peking University, Beijing, China, ²Bayer, Beijing, China
- PCV19 J6 ESTIMATING THE ECONOMIC BURDEN OF HEART FAILURE PATIENTS IN KOREA**
Kim H¹, Kim J¹, Ku H², Lee E³, Ko S¹, ¹Novartis Korea, Seoul, South Korea, ²College of Pharmacy, Sungkyunkwan University, Suwon, South Korea, ³Sungkyunkwan University, Suwon, South Korea
- PCV20 J7 LONG-TERM HEALTH-RELATED ECONOMIC BURDEN OF ADULT CONGENITAL HEART DISEASES IN HONG KONG**
Lee VW, Fung A, Fong T, Yan BP, The Chinese University of Hong Kong, Shatin, Hong Kong
- PCV21 J8 HORIZONTAL AND VERTICAL FINANCIAL EQUITY IN HOSPITALIZED CARDIOVASCULAR PATIENTS; A CASE STUDY IN IRAN**
Davari M¹, Khorasani E¹, Maracy MR², ¹Tehran University of Medical Sciences, Tehran, Iran (Islamic Republic of), ²Isfahan University of Medical Sciences, Isfahan, Iran (Islamic Republic of)
- PCV22 J9 DIRECT ECONOMIC BURDEN IN PATIENTS WITH CEREBRAL VENOUS THROMBOSIS AT A TERTIARY CARE HOSPITAL IN SOUTH INDIA**
Prabhu VA, Sitaram A, Radhakrishnan K, Unnikrishnan M, Manipal University, Manipal, India
- PCV23 J10 STROKE TREATMENT COST ANALYSIS FOR CONSIDERATION ON HEALTH COST DETERMINATION USING INA-CBG'S (INDONESIA CASE BASED GROUPS) IN INDONESIA NATIONAL HEALTH INSURANCE PROGRAMME 2014**
Hadning I¹, Fathurrohman F², ¹Gadjah Mada University, Yogyakarta, Indonesia, ²Muhammadiyah Yogyakarta University, Yogyakarta, Indonesia
- PCV24 K1 COST-EFFECTIVENESS OF DIFFERENT STRATEGIES FOR PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP REPLACEMENT IN CHINA**
Yan XY¹, Gu XH², Zhou L³, Lin HW⁴, **Wu B**⁴, ¹Department of Orthopedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China, ²Department of Respiratory, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China, ³Department of Cardiology, Renji Hospital, Shanghai, China, ⁴Medical Decision and Economic Group, Department of Pharmacy, Renji Hospital, Shanghai, China
- PCV25 K2 COST-EFFECTIVENESS ANALYSIS OF LONG-TERM VERSUS SHORT-TERM DUAL ANTIPLATELET THERAPY IN PATIENTS WITH DRUG-ELUTING STENTS**
Jiang M, You J, The Chinese University of Hong Kong, Shatin, Hong Kong
- PCV26 K3 COST-EFFECTIVENESS OF APIXABAN VERSUS WARFARIN IN CHINESE PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION**
Chan E, Li X, Lau C, Anand S, University of Hong Kong, Hong Kong, China
- PCV27 K4 SYSTEMATIC REVIEW, META-ANALYSIS, AND COST-EFFECTIVENESS MODEL OF INVASIVE VERSUS NON-INVASIVE STRATEGY FOR NON-ST ELEVATION ACUTE CORONARY SYNDROME (NSTEMI) IN PATIENTS WITH PRIOR CORONARY ARTERY BYPASS GRAFT (CABG)**
Putri S¹, Briggs A², ¹Center for Health Economics and Policy Studies Faculty of Public Health Universitas Indonesia, Depok, Indonesia, ²University of Glasgow, Glasgow, UK
- PCV28 K5 COST-EFFECTIVENESS ANALYSIS OF SCREENING FOR AND MANAGING IDENTIFIED HYPERTENSION FOR CARDIOVASCULAR DISEASE PREVENTION IN VIETNAM**
Nguyen TP¹, Wright EP², Nguyen T³, C.C.M. S¹, Nguyen T⁴, Postma M¹, ¹University of Groningen, Groningen, The Netherlands, ²Medical Committee Netherlands-Vietnam, Amsterdam, The Netherlands, ³Thai Nguyen General hospital, Thai Nguyen, Viet Nam, ⁴Ha Noi University of Medicine, Ha Noi, Viet Nam
- PCV29 K6 ESTIMATING AN ICER WITH NOAC VERSUS WARFARIN IN ATRIAL FIBRILLATION**
Origasa H¹, Noma H², Teramukai S³, ¹University of Toyama, Toyama, Japan, ²Institute of Statistical Mathematics, Tokyo, Japan, ³Kyoto Prefectural University of Medicine, Kyoto, Japan
- PCV30 K7 COST EFFECTIVENESS ANALYSIS FOR COMBINATION OF ASPIRIN AND WARFARIN VERSUS WARFARIN ALONE IN**

PATIENTS WITH HEART VALVE PROSTHESIS

Elhamamsy M¹, Elsisi GH², Elmazar MM¹, Taha AS¹, Awad BF¹, **sharaf Eldin AM**^{2,1}, Ain Shams University, Cairo, Egypt, ²the american university in Cairo, Cairo, Egypt

PCV31 K8 A MODEL-BASED COST-EFFECTIVENESS ANALYSIS OF B-TYPE NATRIURETIC PEPTIDE MONITORING IN PATIENTS WITH HEART FAILURE

Mohiuddin S¹, Hollingworth W¹, Maishman R¹, Dayer M², MacLeod J¹, McDonagh T³, Purdy S¹, Reeves B¹, Rogers C¹, Pufulete M^{1,1}, University of Bristol, Bristol, UK, ²Taunton and Somerset NHS Trust, Somerset, UK, ³King's College London, London, UK

PCV32 K9 A COST-UTILITY ANALYSIS OF DABIGATRAN, ENOXAPARIN, AND USUAL CARE FOR VENOUS THROMBOPROPHYLAXIS AFTER HIP OR KNEE REPLACEMENT SURGERY IN THAILAND

Kotirum S¹, **Chongmelaxme B**², Chaiyakunapruk N^{1,1}, Monash University Malaysia, Selangor, Malaysia, ²Naresuan University, Phitsanulok, Thailand

CARDIOVASCULAR DISORDERS - Patient-Reported Outcomes & Patient Preference Studies

PCV33 K10 MEASUREMENT OF ADHERENCE TO ANTI-HYPERTENSIVE DRUGS IN ASIA

Ma Q¹, Kao C¹, Miles G¹, Chen G^{2,1}, Costello Medical Singapore Pte Ltd, Singapore, Singapore, ²Costello Medical Consulting Ltd, Cambridge, UK

PCV34 L1 THE OUTCOMES OF A PHARMACEUTICAL CARE ASSISTANCE PROGRAM IN A ROMANIAN COMMUNITY PHARMACY

Mic OC¹, Turcu-Stolica A^{2,1}, University of Medicine and Pharmacy, Craiova, Romania, ²University of Medicine and Pharmacy Craiova, Craiova, Romania

PCV35 L2 EFFECTS OF PHARMACIST COUNSELING ON OUTPATIENTS RECEIVING WARFARIN AT DR. HASAN SADIKIN BANDUNG HOSPITAL

Putriana NA, Universitas Padjadjaran, bandung, Indonesia

PCV37 L3 IMPROVING MEDICATION ADHERENCE THROUGH CALENDAR PACKAGING: RESULTS OF A RANDOMIZED CONTROLLED TRIAL AMONG HYPERTENSIVE PATIENTS IN MALAYSIA

Tan BY, Shafie AA, Hassali MA, **Saleem F**, Universiti Sains Malaysia, Penang, Malaysia

PCV38 L4 ASSESSMENT OF UTILITY FOR HEART FAILURE USING VISUAL ANALOGUE SCALE(VAS), TIME-TRADE OFF(TTO) AND EUROQOL-5 DIMENSION(EQ-5D) IN THE KOREAN GENERAL POPULATION

Lee JY, Lee E, School of Pharmacy, Sungkyunkwan university, Suwon, South Korea

PCV39 L5 A SYSTEMATIC REVIEW OF CARDIOVASCULAR EVENT UTILITIES IN ASIA

Blieden M¹, Szatkowski A¹, Cheng L², **Gandra SR**^{3,1}, Evidera, Lexington, MA, USA, ²Amgen, Inc., Thousand Oaks, CA, USA, ³Amgen Inc., Thousand Oaks, CA, USA

PCV40 L6 A SYSTEMATIC REVIEW COMPARING STUDIES OF CARDIOVASCULAR EVENT UTILITIES BY GEOGRAPHIC REGION

Blieden M¹, Szatkowski A¹, Cheng L², **Gandra SR**^{3,1}, Evidera, Lexington, MA, USA, ²Amgen, Inc., Thousand Oaks, CA, USA, ³Amgen Inc., Thousand Oaks, CA, USA

PCV41 L7 SATISFACTION LEVEL OF PATIENTS, PHYSICIANS, AND PRIVATE PRIMARY HEALTHCARE CENTER MANAGERS WITH CHRONIC DISEASE MANAGEMENT PROGRAM IN INDONESIA

Sinuraya RK, Abdulah R, Diantini A, Suwantika AA, Universitas Padjadjaran, Sumedang, Indonesia

PCV42 L8 THE USE OF ALHIJAMA AS COMPLIMENTARY TREATMENT IN HYPERTENSION

Ibrahim I¹, Hassali MA², Saleem F^{1,1}, Universiti Sains Malaysia, Penang, Malaysia, ²School of pharmaceutical sciences, Universiti Sains Malaysia, Penang, Malaysia

PCV43 L9 A REVIEW OF STUDIES OF HEALTH-RELATED QUALITY OF LIFE PERFORMED IN CHINESE-SPEAKING ISCHEMIC HEART DISEASE PATIENTS

Luan L, Hu H, Li SC, University of Newcastle, Callaghan, NSW, Australia

PCV44 L10 PSYCHOMETRIC VALIDATION OF ANTI-CLOT TREATMENT SCALE IN JAPANESE PATIENTS WITH ATRIAL FIBRILLATION

Cano S¹, Koretsune Y², Kumagai K³, Uchiyama S⁴, Yamashita T⁵, Yasaka M⁶, Akiyama S⁷, Briere J⁸, Sakaguchi T⁹, Okayama Y⁹, **Watanabe Fujinuma E**^{7,1}, Modus Outcomes, Stotfold, UK, ²National Hospital Organization, Osaka National Hospital, Osaka, Japan, ³Fukuoka Sanno Hospital, Fukuoka, Japan, ⁴Sanno Hospital, Tokyo, Japan, ⁵The Cardiovascular Institute, Tokyo, Japan, ⁶Kyushu Medical Center, Fukuoka, Japan, ⁷Bayer Yakuin, Ltd., Tokyo, Japan, ⁸Bayer Pharma AG, Berlin, Germany, ⁹Bayer Yakuin, Ltd., Osaka, Japan

PCV45 M1 HEALTH RELATED QUALITY OF LIFE AMONG PATIENTS WITH HEART FAILURE IN SOUTH KOREA

Lee B¹, Kim E¹, Yang B¹, **Kwon H**^{2,1}, Seoul National University, Seoul, South Korea, ²Harvard T.H. Chan School of Public Health, Boston, MA, USA

PCV46 M2 INFLUENCE OF PERCEIVED RISK ON WILLINGNESS TO PAY FOR DIAGNOSIS OF CARDIOVASCULAR DISEASES

Maharajan M¹, Rajiah K², Kelly Num S², NGU WY¹, Lau Heng Ying S¹, Yan YC¹, Shie Lin Y^{1,1}, International Medical University Malaysia, Kuala Lumpur, Malaysia, ²International Medical University, Kuala Lumpur, Malaysia

CARDIOVASCULAR DISORDERS - Health Care Use & Policy Studies

- PCV47 M3** **PRESCRIBING PATTERN OF ANTI HYPERTENSIVE AGENTS IN A TERTIARY CARE HOSPITAL OUTPATIENT DEPARTMENT**
Gonthi A¹, Bairy S¹, Vattipelli M², M V³, ¹St.Peter's Institute of Pharmaceutical sciences, Warangal, India, ²St peter's Institute of Pharmaceutical sciences, Warangal, India, ³Talla Padmavati College of Pharmacy, Warangal, India
- PCV48 M4** **DRUG USE ANALYSIS OF PATIENTS WITH HYPERTENSION AND DIABETES IN SHANGHAI, CHINA: BASED ON DRUG BIDDING DATABASE OF SHANGHAI MEDICAL INSTITUTIONS**
Yang Y, He J, Zhang X, Shanghai Medical Information Center (Shanghai Health Development Research Center), Shanghai, China
- PCV49 M5** **THE RISKS OF USING CHINESE MEDICATIONS ASSOCIATED WITH CARDIOVASCULAR DISEASE, DIABETES MELLITUS, AND CHRONIC KIDNEY DISEASE- A SYSTEMATIC REVIEW**
Wang Y¹, Chek W¹, Lee W¹, Tsai H², Lin S³, Lin H¹, ¹China Medical University, Taichung, Taiwan, ²Providence University, Taichung City, Taiwan, ³China Medical University Hospital, Taichung, Taiwan
- PCV50 M6** **HEALTH CARE APPLICABILITY OF A PATIENT-CENTRIC WEB PORTAL FOR PATIENTS' MEDICATION EXPERIENCE**
Hong SH¹, Alruthia Y², Lee W¹, ¹Seoul National University, Seoul, South Korea, ²King Saud University, Riyadh 12372, Saudi Arabia
- PCV51 M7** **THE COST OF POST STROKE TREATMENT AT SELECTED PUBLIC PRIMARY CARE HEALTHCENTRES IN MALAYSIA**
Abdul Aziz AF¹, Muhammad Nur A², Sulong S¹, Aljunid SM³, ¹Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia, ²Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia, ³Kuwait University, Kuwait City, Kuwait
- PCV52 M8** **THE IMPACT OF ISCHEMIC STROKE ON ATRIAL FIBRILLATION-RELATED HEALTHCARE COST: A SYSTEMATIC REVIEW**
Li X, Au-Doung L, Chan E, University of Hong Kong, Hong Kong, China
- PCV53 M9** **THE IMPACT OF AGE- AND GENDER- DIFFERENCES IN DIRECT HOSPITALIZATION COSTS FOR HEMORRHAGIC STROKE IN-PATIENTS WITH BASIC MEDICAL INSURANCE SCHEME FOR URBAN RESIDENTS OF CHINA**
Ma Y¹, Yang L², Fang Y¹, ¹Beijing University of Chinese Medicine, Beijing, China, ²China Health Insurance Research Association, Beijing, China
- PCV54 M10** **QUANTIFYING INFORMAL VERSUS FORMAL CARE, AND FINANCIAL CAREGIVER BURDEN, FOR STROKE PATIENTS IN ASIA: A STRUCTURED LITERATURE REVIEW**
Wayman SA¹, Langford BE¹, Buchanan-Hughes AM¹, Chen G², ¹Costello Medical Consulting Ltd., Cambridge, UK, ²Costello Medical Singapore, Singapore, Singapore
- PCV55 N1** **BAYESIAN NETWORK OF DISEASE HISTORY**
Nakamura Y, Milliman, Tokyo, Japan
- PCV56 N2** **PRESCRIPTION TREND IN ANTIHYPERTENSIVE DRUGS IN MUMBAI AND SUBURBS: A SURVEY**
Desai GV, Desai NS, D'souza DM, Kumar MS, Ningoo MS, Shah RS, Majumdar AS, BOMBAY COLLEGE OF PHARMACY, MUMBAI, India
- PCV57 N3** **IDENTIFICATION OF STATIN INTOLERANCE: RESULTS FROM A SURVEY OF SOUTH KOREAN CLINICIANS**
McKendrick J¹, Gandra SR², **Cheng L**³, Hovingh GK⁴, Dent R³, Wieffer H¹, Catapano AL⁵, Oh P⁶, Rosenson RS⁷, Stroes ES⁴, ¹PRMA Consulting Ltd, Fleet, UK, ²Amgen Inc., Thousand Oaks, CA, USA, ³Amgen, Inc., Thousand Oaks, CA, USA, ⁴Academic Medical Center, Amsterdam, The Netherlands, ⁵University of Milano and IRCCS Multimedica, Milano, Italy, ⁶Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁷Mount Sinai Icahn School of Medicine, Mount Sinai Hospital, New York, NY, USA
- PCV58 N4** **MANAGEMENT OF PATIENTS WITH STATIN INTOLERANCE IN JAPAN, SOUTH KOREA AND TAIWAN: COMPARISON OF RESULTS FROM A CLINICIAN SURVEY**
Kajinami K¹, McKendrick J², Gandra SR³, **Cheng L**⁴, Hovingh G⁵, Dent R⁴, Wieffer H², Catapano AL⁶, Oh P⁷, Rosenson RS⁸, Stroes ES⁵, ¹Kanazawa Medical University, Uchinada, Japan, ²PRMA Consulting Ltd, Fleet, UK, ³Amgen Inc., Thousand Oaks, CA, USA, ⁴Amgen, Inc., Thousand Oaks, CA, USA, ⁵Academic Medical Center, Amsterdam, The Netherlands, ⁶University of Milano and IRCCS Multimedica, Milano, Italy, ⁷Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁸Mount Sinai Icahn School of Medicine, Mount Sinai Hospital, New York, NY, USA
- PCV59 N5** **IDENTIFICATION OF STATIN INTOLERANCE: RESULTS FROM A SURVEY OF CLINICIANS IN TAIWAN**
Kajinami K¹, McKendrick J², **Gandra SR**³, Cheng L⁴, Hovingh GK⁵, Dent R⁴, Wieffer H², Catapano AL⁶, Oh P⁷, Rosenson RS⁸, Stroes ES⁵, ¹Kanazawa Medical University, Uchinada, Japan, ²PRMA Consulting Ltd, Fleet, UK, ³Amgen Inc., Thousand Oaks, CA, USA, ⁴Amgen, Inc., Thousand Oaks, CA, USA, ⁵Academic Medical Center, Amsterdam, The Netherlands, ⁶University of Milano and IRCCS Multimedica, Milano, Italy, ⁷Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁸Mount Sinai Icahn School of Medicine, Mount Sinai Hospital, New York, NY, USA
- PCV60 N6** **IDENTIFICATION OF STATIN INTOLERANCE: RESULTS FROM A SURVEY OF CLINICIANS IN JAPAN**
McKendrick J¹, **Gandra SR**², Hovingh GK³, Dent R⁴, Wieffer H¹, Catapano AL⁵, Oh P⁶, Rosenson RS⁷, Stroes ES³, ¹PRMA Consulting Ltd, Fleet, UK, ²Amgen Inc., Thousand Oaks, CA, USA, ³Academic Medical Center, Amsterdam, The Netherlands, ⁴Amgen, Inc., Thousand Oaks, CA, USA, ⁵University of Milano and IRCCS Multimedica, Milano, Italy, ⁶Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁷Mount Sinai Icahn School of Medicine, Mount Sinai Hospital, New York, NY, USA
- PCV61 N7** **THE ADOPTION OF ROLES BY PRIMARY CARE PROVIDERS DURING IMPLEMENTATION OF THE NEW CHRONIC**

DISEASE GUIDELINES IN URBAN MONGOLIA: A QUALITATIVE STUDY

Chimeddamba O., Monash University, Ulaanbaatar, Mongolia

NEUROLOGICAL DISORDERS - Clinical Outcomes Studies

- PND1 N8 PREVALENCE AND PATIENT CHARACTERISTICS OF MULTIPLE SCLEROSIS (MS) IN JAPAN**
Ogino M¹, Shiozawa A², Ohta H³, Okamoto S³, Hiroi S³, Otake K³, Takeshima T⁴, Iwasaki K⁴, Kawachi I⁵,¹Kitasato University School of Medicine, Sagami-hara, Japan, ²Takeda Pharmaceuticals International, Inc, Deerfield, IL, USA, ³Takeda Pharmaceutical Company Ltd., Tokyo, Japan, ⁴Milliman, Tokyo, Japan, ⁵Niigata University University Medical and Dental Hospital, Niigata, Japan
- PND2 N9 THE STRUCTURE AND VASCULARIZATION OF CHOROID PLEXUS OF BRAIN IN CHILDREN AGED FROM 0-3 YEARS OLD**
Byambasuren T., Amgalanbaatar A, Dorjkhoo A, Mongolian national university of medical sciences, Ulaanbaatar, Mongolia
- PND3 N10 COMPARATIVE EFFECTIVENESS OF PHARMACOLOGICAL INTERVENTIONS FOR PREVENTING MIGRAINE IN CHILDREN AND ADOLESCENT: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS**
Saokaew S¹, Sawangjit R², Lai N³, Suan-ek P⁴, Piromyaporn M¹, Visudtibhan A⁵, Thampratankul L⁵, Chaiyakunapruk N⁶,¹University of Phayao, Muang, Phayao, Thailand, ²Maharakham University, Muang, Thailand, ³Taylor's University Lakeside Campus, -, Malaysia, ⁴University of Phayao, Muang, Phayao, Thailand, ⁵Mahidol University, Bangkok, Thailand, ⁶Monash University Malaysia, Selangor, Malaysia
- PND4 O1 REAL-WORLD OUTCOMES AND RESOURCE UTILISATION FOLLOWING ONABOTULINUMTOXINA TREATMENT FOR SEVERE LOWER LIMB FOCAL SPASTICITY IN ADULTS – DATABASE ANALYSIS AT AN AUSTRALIAN HYPERTONICITY CLINIC**
Frost MJ¹, Cave C², Baguley R², Tan J³,¹Allergan Australia, Gordon, NSW, Australia, ²Princess Alexandra Hospital, Woolloongabba, QLD, Australia, ³Allergan Pte Ltd, Singapore, Singapore
- PND5 O2 A REVIEW OF TREATMENT ON ALZHEIMER'S DISEASE IN CHINA**
Yang K¹, Li SC²,¹Bengbu Medical College, Bengbu, China, ²University of Newcastle, Callaghan, Australia
- PND6 O3 POTENTIAL FACTORS PREDICTING THE RESPONSE IN THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER CHILDREN WITH ATOMOXETINE IN ASIA PACIFIC REGION**
Chen Y., Zhang YL, Zhang X, Wu SH,¹Lilly Suzhou Pharmaceutical Company, Ltd., Shanghai, China
- PND7 O4 EPIDEMIOLOGICAL PROFILING OF CHRONIC HEADACHE PATIENTS AT A PUBLIC TERTIARY CARE SETTING IN INDIA**
Najmi AK¹, Hoda MU¹, Hussain S¹, Habib A², Kapur P², Anwar A², Akhtar M¹, Aquil M¹,¹Faculty of Pharmacy, Jamia Hamdard, Hamdard University, New Delhi, India, ²Hamdard Institute of Medical Sciences and Research (HIMSR), New Delhi, India

NEUROLOGICAL DISORDERS - Cost Studies

- PND8 O5 DETERMINATION OF SERUM CARBAMAZEPINE CONCENTRATION USING DRIED BLOOD SPOT SPECIMENS FOR RESOURCE LIMITED SETTINGS**
Das S., Fleming DH, Mathew BS, Winston A B, Prabhakar AT, Alexander M,¹Christian Medical College, Vellore, India
- PND9 O6 AN AUSTRALIAN NATIONAL COST OF ILLNESS STUDY FOR HEREDITARY HAEMOCHROMATOSIS**
de Graaff BL¹, Neil A¹, Sanderson K¹, Yee KC², Palmer AJ¹,¹Menzies Institute for Medical Research, Hobart, Australia, ²University of Tasmania, Hobart, Australia
- PND10 O7 COST-EFFECTIVENESS OF POPULATION SCREENING FOR HAEMOCHROMATOSIS IN AUSTRALIA: A STATE-TRANSITION MODEL**
de Graaff BL¹, Si L², Neil A¹, Yee KC², Sanderson K¹, Gurrin LC³, Palmer AJ¹,¹Menzies Institute for Medical Research, Hobart, Australia, ²University of Tasmania, Hobart, Australia, ³University of Melbourne, Melbourne, Australia
- PND11 O8 COST-EFFECTIVENESS OF NEWER ANTIEPILEPTIC DRUGS (AEDS) FOR MANAGEMENT OF PARTIAL EPILEPSY IN CHILDREN IN MALAYSIA**
Mohd Tahir NA¹, Thomas P², Makmor Bakry M³, Ali A⁴, Li SC¹,¹University of Newcastle, Callaghan, NSW, Australia, ²Taylor's University, Selangor, Malaysia, ³Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia, ⁴Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia

NEUROLOGICAL DISORDERS - Patient-Reported Outcomes & Patient Preference Studies

- PND12 O9 ADHERENCE, HEALTHCARE RESOURCE UTILIZATION AND DIRECT MEDICAL COSTS AMONG PATIENTS WITH ALZHEIMER'S DISEASE IN TIANJIN, CHINA**
Xie S., Wu J,¹Tianjin University, Tianjin, China
- PND13 O10 ASSESSING HEALTH-STATE UTILITY VALUES IN AUSTRALIAN PEOPLE WITH MULTIPLE SCLEROSIS**
Ahmad H¹, van der Mei I², Taylor B², Palmer AJ²,¹University of Tasmania, Hobart, Australia, ²University of Tasmania, Hobart, Australia

NEUROLOGICAL DISORDERS - Health Care Use & Policy Studies

- PND14 P1 EFFICACY AND SAFETY OF AZATHIOPRINE FOR MULTIPLE SCLEROSIS: A RAPID REVIEW**
LU J., LI YP,¹West Hospital of SU, Chengdu, China
- PND15 P2 COST-EFFECTIVENESS ANALYSIS OF NON-INVASIVE PRENATAL TESTING FOR DOWN'S SYNDROME IN CHINA**

Xu Y¹, Chen Y², LI N¹, Ming J^{2,1}Fudan University, ShangHai, China, ²Fudan University, Shanghai, China

PND16 P3 THE CURRENT TREATMENT OF PARKINSON'S DISEASE IN JAPAN

Uda A¹, Kuwabara H¹, Shiozawa A², Hiroi S¹, Yamabe K¹, Okamoto S¹,¹Takeda Pharmaceutical Company Ltd., Tokyo, Japan, ²Takeda Pharmaceuticals International, Inc, Deerfield, IL, USA

RESPIRATORY-RELATED DISORDERS - Clinical Outcomes Studies

PRS1 P4 EFFECTS OF A CHRONIC OBSTRUCTIVE PULMONARY DISEASE INTEGRATED CARE PATHWAY PROGRAMME IN SINGAPORE

Yu Fan S, JurongHealth, Singapore, Singapore

PRS2 P5 EFFECTIVENESS OF CLINICAL PHARMACIST INTERVENTION ON DIRECT MEDICAL COST IN CHRONIC OBSTRUCTIVE PULMONARY DISORDER PATIENTS - A RANDOMIZED CONTROLLED STUDY

Suhaj A¹, Unnikrishnan MK², Mohan MK¹, Kunhikkatta V², Rao C M^{3,1}Manipal University, Manipal, India, ²Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India, ³Manipal College of Pharmaceutical Sciences, Manipal, India

PRS3 P6 MEPOLIZUMAB FOR THE TREATMENT OF CHRONIC ASTHMA. A META-ANALYSIS OF RANDOMIZED PLACEBO-CONTROLLED TRIALS

Kanukula R, Likhari N, Dang A, MarksMan Healthcare Solutions LLP, Health Economics and Outcomes Research (HEOR) and RWE (Real World Evidence), Navi Mumbai, India

PRS4 P7 VALIDATION OF A NOVEL TOOL TO PREDICT OUTCOMES IN PATIENTS WITH NOSOCOMIAL PNEUMONIA

Srinivasan M¹, Gadekari S¹, Shetty N¹, Vijayanarayana K², Thunga G¹, Rao N K^{3,1}Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India, ²Dept. of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, Karnataka State., India, ³Manipal University, Manipal, India

RESPIRATORY-RELATED DISORDERS - Cost Studies

PRS5 P8 TAX LOSSES AND GAINS ATTRIBUTED TO SMOKING CESSATION IN KOREA

Connolly M¹, Kotsopoulos N², Chen S³, Hwang S^{4,1}University of Groningen, Groningen, The Netherlands, ²Health Policy Institute, Athens, Greece, ³Pfizer Inc, Hong Kong, Hong Kong, ⁴Pfizer Korea, Seoul, South Korea

PRS6 P9 COMPARISON OF HEALTH CARE UTILIZATION AND COST DEPENDING ON THE SEVERITY OF ASTHMA IN ADULTS: ANALYSIS OF THE KOREAN NATIONAL HEALTH INSURANCE CLAIMS DATABASE

Lee YJ, Lee E, School of Pharmacy, Sungkyunkwan University, Suwon, South Korea

PRS7 P10 DIRECT COST ANALYSIS AND COST EFFECTIVENESS ANALYSIS OF CHRONIC OBSTRUCTION PULMONARY DISEASE IN FATMAWATI PUBLIC HOSPITAL

Anwar Y¹, Afdhal AF¹, Anggraini Y^{2,1}17 August 1945 Jakarta University, Jakarta, Indonesia, ²Pancasila University, Jakarta, Indonesia

PRS8 Q1 THE ECONOMIC BURDEN OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN CHINA: A SYSTEMATIC LITERATURE REVIEW

Qu KQ¹, Selya-Hammer C², Chew VC^{2,1}Amaris, Toronto, ON, Canada, ²Amaris, London, UK

PRS9 Q2 COPD UNCOVERED: HEALTH CARE RESOURCE USE AND COST OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN JAPAN

Igarashi A¹, Fukuchi Y², Hirata K³, Ichinose M⁴, Nagai A⁵, Nishimura M⁶, Lara N⁷, Murata S⁸, Gruenberger J^{9,1}The University of Tokyo Tokyo, Tokyo, Japan, ²Juntendo University Tokyo, Tokyo, Japan, ³Osaka City University, Osaka, Japan, ⁴Tohoku University, Sendai, Japan, ⁵ShinYurigaoka General Hospital, Kawasaki, Japan, ⁶Hokkaido University, Sapporo, Japan, ⁷IMS Health, Barcelona, Spain, ⁸Novartis Pharma, K.K., Tokyo, Japan, ⁹Novartis Pharma, AG, Basel, Switzerland

PRS10 Q3 HOSPITAL RESOURCE UTILIZATION OF PATIENTS OVER 40 YEARS OLD WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN SOUTH KOREA

Umareddy I¹, Hyunjung A², Jieun K^{2,1}Kantar Health, Singapore, Singapore, ²Kantar Health Korea, Seoul, Korea, The Democratic People's Republic of

RESPIRATORY-RELATED DISORDERS - Patient-Reported Outcomes & Patient Preference Studies

PRS11 Q4 COMPARISON OF EQUITY WEIGHTS OF VARIOUS ADVERSE CONSEQUENCES OF TOBACCO USE: A BEST-WORST SCALING FOR TWO TYPES OF CHINESE GENERAL PUBLIC

Mori T, Tsuge T, Konan University, Kobe, Japan

PRS12 Q5 HEALTH-RELATED QUALITY OF LIFE OF INDONESIAN ASTHMA PATIENTS

Perwitasari D, Retnowati E, Supadmi W, University of Ahmad Dahlan Yogyakarta, Yogyakarta, Indonesia

RESPIRATORY-RELATED DISORDERS - Health Care Use & Policy Studies

PRS13 Q6 ACUTE RESPIRATORY DISTRESS SYNDROME PROFILE AT A TERTIARY CARE TEACHING HOSPITAL IN SOUTH INDIA

Raj A, Manipal University, Manipal, India

PRS14 Q7 PATTERNS OF MEDICATION REGIMEN COMPLEXITY OVER ONE-YEAR FOLLOW UP IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS

Chong SI¹, Wu S², Cheng W³, Chen J⁴, Lin H⁴,¹Kaiser Permanente Southern California, San Diego, CA, USA, ²Mennonite Christian Hospital, Hualien, Taiwan, ³China Medical University Hospital, Taichung, Taiwan, ⁴China Medical University, Taichung, Taiwan

PRS15 Q8 HEALTH RESOURCE USE AND COST UNDER PAY ON FEE AND CASE-BASED PAYMENT IN HOSPITALIZED PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN CHINA

Ye J¹, Zhang J², Gao S¹, Ma Y³, **Liu Q**¹,¹Beijing Brainpower Pharma Consulting Co. Ltd., Beijing, China, ²China Health Insurance Research Association, Beijing, China, ³Beijing University of Chinese Medicine, Beijing, China

PRS16 Q9 COMPARATIVE EFFECTIVENESS ANALYSIS FOR SMOKING CESSATION MEDICATIONS

Chang P¹, Lo P², Chang H², Hsueh K³, Tsai Y², **Lan T**⁴,¹Department of Medicine, Stanford University School of Medicine, California, CA, USA, ²Institute of Health and Welfare Policy, National Yang-Ming University, Taipei, Taiwan, ³Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ⁴Center for Geriatrics and Gerontology Taichung Veterans General Hospital, Taichung, Taiwan

PRS17 Q10 COMPARATIVE EFFECTIVENESS ANALYSIS FOR SMOKING CESSATION MEDICATIONS AND RELAPSE

Chang P¹, Chang H², Wang I², Lin S², Tsai Y³, **Lan T**⁴,¹Department of Medicine, Stanford University School of Medicine, California, CA, USA, ²National Yang Ming University, Taipei, Taiwan, ³Institute of Health and Welfare Policy, National Yang-Ming University, Taipei, Taiwan, ⁴Center for Geriatrics and Gerontology Taichung Veterans General Hospital, Taichung, Taiwan

PRS18 R1 ONE-YEAR FOLLOW-UP OF MEDICATION REGIMEN COMPLEXITY AMONG MODERATE COPD PATIENTS WITH OR WITHOUT EARLIER USE OF INHALED CORTICOSTEROIDS

Wu S¹, Cheng W², Chong SI³, Chen J⁴, Lin H⁴,¹Mennonite Christian Hospital, Hualien, Taiwan, ²China Medical University Hospital, Taichung, Taiwan, ³Kaiser Permanente Southern California, San Diego, CA, USA, ⁴China Medical University, Taichung, Taiwan

PRS19 R2 DRUG UTILIZATION EVALUATION STUDY OF SILDENAFIL IN A TERTIARY CARE TEACHING HOSPITAL IN INDIA – A RETROSPECTIVE ANALYSIS

Babu B¹, **Reji RS**¹, Pathiraj JP¹, Marupuru S², Shekhar M², SR G²,¹Manipal University, Manipal, India, ²MCOPS, Manipal University, Manipal, India

PRS20 R3 ANTI-ASTHMATIC DRUG PRESCRIBING PATTERN ASSESSMENT AT MEDICAL REIMBURSEMENT IN EMPLOYEES HEALTH CARE FACILITY OF BANARAS HINDU UNIVERSITY

Priya D, Purohit S, Pandey B, INSTITUTE OF MEDICAL SCIENCES, VARANASI, India

PRS21 R4 INHALED ILOPROST THERAPY AND PULMONARY ARTERIAL HYPERTENSION: EXPERIENCE IN A FORMULARY DECISION STUDY

Koh L, Lai L, Nova Southeastern University, Davie, FL, USA

SYSTEMIC DISORDERS/CONDITIONS - Clinical Outcomes Studies

PSY1 R5 ACUPUNCTURE TREATMENT FOR NEUROPATHIC PAIN IN SPINAL CORD INJURY

Son C, Lee B, Lee GE, National Rehabilitation Center, Seoul, South Korea

PSY2 R6 COMPARATIVE EFFECTIVENESS OF INTERVENTIONS ON NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD): A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

Sawangjit R¹, Chongmelaxme B², Phisalprapa P³, **Saokaew S**⁴, Thakkinstant A³, Kowdley K⁵, Chaiyakunapruk N⁶,¹Maharakham University, Muang, Thailand, ²Naresuan University, Phitsanulok, Thailand, ³Mahidol University, Bangkok, Thailand, ⁴University of Phayao, Muang, Phayao, Thailand, ⁵Swedish Medical Center, Seattle, WA, USA, ⁶Monash University Malaysia, Selangor, Malaysia

PSY3 R7 THE IMPACT OF MEDICAL INSURANCE COVERAGE OF IMATINIB AND MOLECULAR MONITORING FREQUENCY ON OUTCOMES IN TREATMENT OF CHRONIC MYELOID LEUKAEMIA (CML): A REAL WORLD EVIDENCE IN CHINA

Chen S¹, Sheng G¹, Zhang R¹, Miao M¹, Wu D¹, Xiong T², Tan SC³, Liu C⁴,¹The First Affiliated Hospital of Soochow University, Suzhou, China, ²IMS Health, Shanghai, China, ³IMS Health, Singapore, Singapore, ⁴Novartis Pharmaceuticals (China) Oncology, Beijing, China

PSY4 R8 CLINICAL EVALUATION OF PUNARNAVADI MANDOORA AND TRYUSHANADI LOHA IN PATIENTS OF OBESITY

Acharya S¹, Nagappa AN², Santhosh K Sk¹,¹PG Dept. of Kayachikitsa, Muniyal Institute of Ayurveda Medical Sciences, Manipal, India, ²Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India

PSY5 R9 COMPARATIVE SAFETY AND EFFECTIVENESS OF CARBAPENEMS VERSUS ALTERNATIVE ANTIBIOTICS FOR BACTERAEMIA DUE TO ENTEROBACTERIACEAE PRODUCING EXTENDED-SPECTRUM β -LACTAMASE IN EMPIRICAL THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS

Son SK, **Park JJ**, Lee NR, Park D, National Evidence-based Healthcare Collaborating Agency, Seoul, South Korea

PSY6 R10 PREVALENCE AND MANAGEMENT OF ANEMIA IN PATIENTS OF CHRONIC KIDNEY DISEASE AT A TERTIARY CARE PUBLIC TEACHING HOSPITAL: EVIDENCE FROM A CROSS SECTIONAL STUDY

Ahlawat R¹, Tiwari P¹, D'Cruz S²,¹National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar (Mohali), Punjab, India, ²Government Medical College & Hospital, Chandigarh, India

PSY7 S1 CHILDHOOD STUNTING, WASTING AND OBESITY IN INDONESIA: EVIDENCE FROM THE INDONESIAN FAMILY LIFE SURVEY

SYSTEMIC DISORDERS/CONDITIONS - Cost Studies

- PSY8 S2 **BUDGET IMPACT ANALYSIS OF DASATINIB IN IMATINIB-RESISTANT OR-INTOLERANT PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) IN THE CHINESE SETTING**
Wu B, Ren Ji Hospital, Shanghai, China
- PSY9 S3 **COST BURDEN OF CROHN'S DISEASE AND ULCERATIVE COLITIS IN THE UNITED STATES**
Chen C, Xiao H, University of Florida, Gainesville, FL, USA
- PSY10 S4 **THE ECONOMIC BURDEN OF FIBROMYALGIA IN JAPAN**
Ebata N¹, Lee LK², Hlavacek P³, DiBonaventura M⁴, Cappelleri JC⁵, Sadosky A^{3,1}, Pfizer Japan, Tokyo, Japan, ²Kantar Health, Foster City, CA, USA, ³Pfizer Inc., New York, NY, USA, ⁴Kantar Health, New York, NY, USA, ⁵Pfizer, Inc., Groton, CT, USA
- PSY11 S5 **COST ASSESSMENT OF IMPLEMENTATION OF IMMUNE TOLERANCE INDUCTION IN KMC HOSPITAL**
Babu B, Kumar JP, Manipal University, Manipal, India
- PSY13 S6 **SOCIETAL IMPLICATIONS OF MEDICAL INSURANCE COVERAGE FOR IMATINIB AS FIRST-LINE TREATMENT OF CHRONIC MYELOID LEUKAEMIA IN CHINA: A COST EFFECTIVENESS ANALYSIS**
Chen S¹, Dong C², Sheng G¹, Zhang R¹, Miao M¹, Wu D¹, Xiong T³, Tan SC⁴, Liu C⁵, ¹The First Affiliated Hospital of Soochow University, Suzhou, China, ²Ministry of Human Resources and Social Security of China, Institute of Social Security, Beijing, China, ³IMS Health, Shanghai, China, ⁴IMS Health, Singapore, Singapore, ⁵Novartis Pharmaceuticals (China) Oncology, Beijing, China
- PSY14 S7 **COST-MINIMIZATION ANALYSIS IN POSTOPERATIVE PAIN MANAGEMENT AFTER NON-CARDIAC MAJOR SURGERIES IN CHINA: PARECOXIB VERSUS NONSELECTIVE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND TRAMADOL**
Barra M¹, Remak E¹, Liu D², Xie L³, Abraham L⁴, Sadosky A⁵, Kongnakorn T⁶, ¹Evidera, Budapest, Hungary, ²Pfizer Investment Co., Ltd., Beijing, China, ³Pfizer Investment Co. Ltd., Beijing, China, ⁴Pfizer, Ltd., Walton Oaks, UK, ⁵Pfizer Inc., New York, NY, USA, ⁶Evidera, Bangkok, Thailand

SYSTEMIC DISORDERS/CONDITIONS - Patient-Reported Outcomes & Patient Preference Studies

- PSY15 S8 **A UNIQUE OPPORTUNITY TO ASSESS QUALITY-OF-LIFE CHANGES IN LONG-TERM WAITLISTED BARIATRIC SURGERY PATIENTS USING THE EQ-5D-5L AND AQOL-8D MULTI-ATTRIBUTE UTILITY INSTRUMENTS BEFORE AND THREE MONTHS AFTER BARIATRIC SURGERY: AN EXPLORATORY STUDY**
Campbell JA¹, Hensher M², Venn A¹, Neil A¹, Otahal P¹, Palmer AJ¹, ¹University of Tasmania, Hobart, Australia, ²Tasmanian State Government, Hobart, Australia
- PSY16 S9 **PERCEPTIONS OF THALASSEMIA PATIENTS' ON THALASSEMIA AND ITS TREATMENT: A QUALITATIVE EXPLORATION**
Ismail w¹, Hassali MA², Saleem F², Farooqui M³, ¹Faculty of Health Sciences University Technology MARA, Penang, Malaysia, ²School of pharmaceutical sciences, Universiti Sains Malaysia, Penang, Malaysia, ³Faculty of Pharmacy, Universiti Teknologi MARA, Penang, Malaysia
- PSY17 S10 **QUALITY OF LIFE AND ECONOMIC IMPACT OF NEUROPATHIC PAIN AND FIBROMYALGIA SYNDROME IN CHRONIC BACK PAIN PATIENTS IN TERTIARY CARE**
Yingsakmongkol W¹, Limthongkul W¹, Singhatanadgige W¹, Suthipiniitham P², ¹Chulalongkorn University, Bangkok, Thailand, ²Pfizer (Thailand) Limited, Bangkok, Thailand

SYSTEMIC DISORDERS/CONDITIONS - Health Care Use & Policy Studies

- PSY18 T1 **THE ASSOCIATION WITH PSYCHIATRIC DISEASES AND PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA IN TAIWAN**
Chang C¹, Chu C², Tang C¹, ¹Taipei Medical University, Taipei, Taiwan, ²National Taiwan University Hospital, Taipei, Taiwan
- PSY19 T2 **RARE AND INTRACTABLE DISEASE POLICY REFORM IN JAPAN: A BEFORE AND AFTER ANALYSIS**
Tomita N¹, Nakagawa Y², Kanatani Y¹, ¹National Institute of Public Health, Saitama, Japan, ²National Hospital Organization Shikoku Medical Center for Children and Adults, Zentuji city, Japan
- PSY20 T3 **COMPARE POLICIES AND RESEARCH SITUATION OF RARE DISEASES AND ORPHAN DRUGS BETWEEN CHINA AND OTHER COUNTRIES**
Li T, Shenyang Pharmaceutical University, Shenyang, China
- PSY21 T4 **REAL-WORLD COMPARING INTRAVENOUS BUSULFAN TO TOTAL BODY IRRADIATION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH A JAPANESE DIAGNOSIS PROCEDURE COMBINATION (DPC) DATABASE**
Ota M, Fushimi K, Tokyo Medical and Dental University Graduate School of Medicine, bunkyo-ku, Japan
- PSY22 T5 **CURRENT SITUATION AND PROSPECT OF ORPHAN DRUGS IN CHINA**
SHI H¹, Huang L², Xu L², ¹Astrazeneca(China), Beijing, China, ²Astrazeneca (China), Beijing, China
- PSY23 T6 **MEDICATION COST OF ACUTE MYELOID LEUKEMIA: A DESCRIPTIVE STUDY**
Manan MM, KPJ Healthcare University College, NILAI, Malaysia
- PSY24 T7 **COMPLETE REMISSION AND SURVIVAL RATIO COMPARISON BETWEEN TRANSPLANT AND NON-TRANSPLANT AML**

PATIENTS RECEIVING STANDARD REGIMEN IN A MALAYSIAN HOSPITAL

Manan MM, KPJ Healthcare Univerisity College, NILAI, Malaysia

PSY25 T8 UTILIZATION OF ANTIMICROBIAL AGENTS AT THE HAEMATOLOGY WARD IN A PUBLIC HOSPITAL

Manan MM, KPJ Healthcare Univerisity College, NILAI, Malaysia

PSY26 T9 COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) DISCLOSURE TO THE HEALTH CARE PROVIDERS: A QUALITATIVE INSIGHT FROM MALAYSIA THALASSEMIA PATIENTS

Ismail wl¹, Hassali MA², Farooqui M³, Saleem F^{2,1}, Faculty of Health Sciences University Technology MARA, Penang, Malaysia, ²Universiti Sains Malaysia, Penang, Malaysia, ³Universiti Teknologi MARA, Kepala Batas, Malaysia

PSY27 T10 IMPACT OF NATIONAL ORPHAN DRUG POLICY AND REIMBURSEMENT MECHANISMS OVER THE IMPLEMENTATION OF MANAGED ENTRY AGREEMENTS IN SELECT ASIA-PACIFIC COUNTRIES

Montilva J¹, Xue Y², Degun R^{2,1}, Navigant Consulting, London, UK, ²Navigant Consulting Inc, London, UK